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Repetitive Myocardial Ischemia Promotes Coronary Growth in the
Adult Mammalian Heart
Kory J. Lavine, MD, PhD; Attila Kovacs, MD; Carla Weinheimer, MS; Douglas L. Mann, MD
Background-—Coronary artery disease and ischemic cardiomyopathy represent the leading cause of heart failure and continue to
grow at exponential rates. Despite widespread availability of coronary bypass surgery and percutaneous coronary intervention,
subsequent ischemic events and progression to heart failure continue to be common occurrences. Previous studies have shown
that a subgroup of patients develop collateral blood vessels that serve to connect patent and occluded arteries and restore
perfusion to ischemic territories. The presence of coronary collaterals has been correlated with improved clinical outcomes;
however, the molecular mechanisms governing this process remain largely unknown.
Methods and Results-—To date, no mouse models of coronary arterial growth have been described. Using a closed-chest model of
myocardial ischemia, we have demonstrated that brief episodes of repetitive ischemia are sufﬁcient to promote the growth of both
large coronary arteries and the microvasculature. Induction of large coronary artery and microvascular growth resulted in
improvements in myocardial perfusion after prolonged ischemia and protected from subsequent myocardial infarction. We further
show that repetitive ischemia did not lead to increased expression of classic proangiogenic factors but instead resulted in
activation of the innate immune system and recruitment of macrophages to growing blood vessels.
Conclusions-—These studies describe a novel model of coronary angiogenesis and implicate the cardiac macrophage as a potential
mediator of ischemia-driven coronary growth. ( J Am Heart Assoc. 2013;2:e000343 doi: 10.1161/JAHA.113.000343)
Key Words: coronary • collateral • macrophage • repetitive ischemia • coronary angiogenesis
M yocardial infarction (MI) and ischemic heart diseaseare among the leading causes of mortality in the
industrial world.1 Despite efforts to minimize ischemic
damage through timely revascularization and initiation of
effective medical therapies, many patients go on to experi-
ence recurrent ischemic events and develop heart failure.1,2
Due to disease complexity and anatomical constraints, a
signiﬁcant number of patients are not candidates for either
coronary bypass surgery or percutaneous coronary interven-
tion. As a result, this population has a strikingly high annual
mortality rate compared with those who undergo complete
revascularization.3,4 These unfortunate results underscore the
need for improved revascularization strategies.
Previously, it has been recognized that a subgroup of
patients form collateral vasculature. These blood vessels
connect patent and occluded arteries and restore perfusion to
ischemic territories. Importantly, the presence of coronary
collaterals has been correlated with improved clinical out-
comes in patients with ischemic heart disease. Patients who
develop angiographically visible collateral vasculature have
reduced rates of cardiac mortality and major adverse cardiac
events, compared with patients without collaterals. In addi-
tion, physiological assessment of collateral perfusion as
measure by collateral ﬂow index revealed improved outcomes
in patients with increased collateral ﬂow.5–9 Given these
ﬁndings, there has been considerable excitement focused on
identifying growth factors and signaling pathways that may
promote the growth of new coronary vasculature. This
approach has been termed therapeutic angiogenesis and
involves administration of growth factors or gene therapy to the
injured myocardium. In this context, coronary growth has been
postulated to occur through a combination of angiogenesis and
arteriogenesis.10,11
Little is known regarding the development and growth of
coronary collaterals. In fact, much of the data available
describing mechanisms of collateral growth are derived from
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mouse models of hindlimb ischemia. Innate immune system
activation, increased classic proangiogenic growth factor
expression including ﬁbroblast growth factors and vascular
endothelial growth factors (VEGF), and recruitment of endo-
thelial progenitor cells have been implicated in collateral
growth.12,13 While hindlimb ischemia represents a robust
model of collateralization, it is unclear whether this system
adequately depicts what occurs in the adult heart.
With respect to the heart, particular attention has been
focused on understanding mechanisms of blood vessel
growth in the border zone after experimental MI. In this
setting, increased expression of multiple classic proangiogen-
ic factors has been identiﬁed (ﬁbroblast growth factors,
VEGFs, and angiopoientins) with the ability to trigger coronary
artery growth in animal models. However, these factors have
failed to translate into the clinical arena, as multiple clinical
studies revealed minimal efﬁcacy.14–18 More recently, several
other candidate molecules have been identiﬁed that can
induce coronary angiogenesis after MI including sonic
hedgehog, thymosin b4, PR39, and platelet-derived growth
factor b. Importantly, few of these growth factor have been
demonstrated to promote large coronary artery or collateral
growth.19–27 Together, these data suggest that there are
critical differences between signaling pathways that promote
coronary angiogenesis after MI and coronary growth in
ischemic heart disease.
A key limitation toward understanding how coronary
vascular growth occurs is the paucity of genetically tractable
small animal models. Porcine and rat models have been
described previously,28,29 but these systems are limited to the
use of pharmacologic agents and gene therapy. To date, there
are no published murine models. The development of a mouse
model of coronary growth represents an important step in
elucidating the cellular and molecular mechanisms by which
coronary growth occurs in the adult heart.
Recently, a closed chest animal model has been described
that allows transient and repeated occlusion of the left
anterior descending coronary artery (LAD) in intact mice.30
This system has enabled investigators to study the effects of
ischemia and reperfusion in both the acute and the chronic
setting and avoids interpretative issues related to thoracot-
omy induced inﬂammation.31 With respect to coronary
collateral development, one can modulate this technique to
determine whether brief repeated ischemic events are
sufﬁcient to trigger coronary growth in intact animals. Such
a scenario mirrors stuttering angina, a key trigger of coronary
collateralization in patients with ischemic heart disease.
Importantly, this model combines the power of mouse
genetics with a clinically relevant model of ischemic injury.
Using the closed chest ischemia/reperfusion (I/R) model,
we demonstrate that repetitive brief episodes of LAD ischemia
are sufﬁcient to trigger coronary growth on both the
macrovascular and microvascular levels. Moreover, we dem-
onstrate that ischemia triggered coronary growth protects
from subsequent MI as a result of improved regional coronary
perfusion. Last, we show minimal alterations in classic
proangiogenic growth factor expression and instead implicate
a role for innate immunity and cardiac macrophages in this
process.
Material and Methods
Mouse Model of Ischemia-Induced Coronary
Angiogenesis
The closed-chest model of I/R has been described previously
by Entman and colleagues.30–33 Brieﬂy, 2- to 4-month-old C57/
B6 mice were anesthetized with sodium pentobarbital, intubat-
ed, and mechanically ventilated. A midline incision was made
exposing the heart, and an 8-0 Prolene suture was then placed
around the proximal LAD to maximize the ischemic area. The
suture was then threaded through a 1 mm piece of polyeth-
ylene tubing forming a loose snare. This served as the occluder.
Each end of the suture was exteriorized through the thorax and
stored in a subcutaneous pocket. The skin was then closed over
the exteriorized suture ends with 5-0 Prolene. Instrumented
mice were allowed to recover for 2 weeks before induction of
ischemia. A baseline echocardiogram was then performed to
ensure that LAD ligation did not occur. Ischemia was induced
after anesthetizing the animals with 1.5% isoﬂurane, opening
the skin over the subcutaneous pocket, and exposing the
exteriorized suture. The suture ends were dissected away from
any subcutaneous tissue, and tension was exerted until
ST-segment elevation was seen on the ECG. Ischemia was
conﬁrmed by visualizing wall motion abnormality using simul-
taneous echocardiography. Following 15 minutes of ischemia
time, tension was released and the suture ends were placed
back into the subcutaneous pocket. The skin was then closed
as described earlier. Sham-operated animals underwent the
identical procedure with the exception that tension was not
placed on the suture ends.
Effect of I/R Injury on Coronary Growth and
Infarct Size
We studied 2 groups of mice. First, to determine whether
repetitive ischemia was sufﬁcient to provoke increased coro-
nary growth, we subjected one group of mice to 15 minutes of
I/R every other day for a total of 3 sessions (brief I/R injury).
The appropriate controls consisted of sham-operated animals,
as described earlier. Mice were killed 1 day after the last
episode of ischemic injury. Second, to determine the functional
signiﬁcance of repetitive I/R injury, we subjected mice that had
previously undergone 3 to 6 episodes of brief ischemic injury to
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2 hours of ischemia followed by reperfusion. One hundred
twenty minutes of ischemic injury has been shown to produce
transmural MI in mice.34 Mice were subjected to prolonged I/R
10 days after brief repetitive ischemia, to minimize the
confounding effects of ischemic preconditioning. Following
reperfusion and recovery from anesthesia, echocardiography
was performed to measure the baseline wall motion abnormal-
ity, left ventricular (LV) systolic function, and LV chamber size. A
second echocardiogram was performed 28 days later to
examine recovery of LV structure and function.35,36 Evans blue
staining was performed in the mice subjected to repetitive
ischemia or sham operation to examine area at risk as
described previously.37 Trichrome staining was used to identify
scar and measure infarct size.
Echocardiography
Mouse echocardiography was performed in the Washington
University Mouse Cardiovascular Phenotyping Core facility
using the VisualSonics 770 Echocardiography System. Avertin
(0.005 mL/g) was used for sedation based on previously
established methods of infarct quantitation.38 Both 2-dimen-
sional and M-mode images were obtained in the long- and
short-axis views. Ejection fraction (EF) and LV dimension were
calculated using standard techniques. LV dimension was
normalized to body weight. The akinetic region was calculated
by measuring the area of the akinetic portion of the LV
myocardium and normalizing it to the area of the total LV
myocardium. Measurements were performed on 3 indepen-
dently acquired images per animal, by investigators who were
blinded to experimental group.
Histology, Immunohistochemistry, Terminal
Deoxynucleotidyl Transferase dUTP Nick End
Labeling Staining, and Microﬁl Perfusion Casting
Tissues were ﬁxed in 2% PFA overnight at 4°C, dehydrated in
70% ethyl alcohol, and embedded in parafﬁn. Four micrometer
sections were cut and stained with hematoxylin and eosin. For
chromogenic immunohistochemical staining, 4-lm parafﬁn
sections were deparafﬁnized, rehydrated, peroxidase blocked,
and antigen exposed by boiling in citric acid 10 mmol/L.
Primary antibodies included rat anti-MAC3 1:400 (BD), rabbit
anti-CD11b 1:400 (Abgent), and rat anti-Ly6G 1:50 (BD).
Biotinylated secondary antibodies were purchased from
Vector Laboratories and used at 1:200. Signal was detected
using the Elite ABC Kit (Vector Laboratories). For colabeling
experiments and PECAM staining, tissues were ﬁxed in 2%
paraformaldehyde (PFA) overnight at 4°C, embedded in
Tissue-Tek OCT compound, (Sakura Finetek) inﬁltrated with
sucrose, and frozen, and 10- to 12-lm cryosections were cut.
Primary antibodies used were rat anti-CD31/PECAM 1:200
(BD), mouse anti-SMA-FITC 1:400 (Sigma-Aldrich), and CD11b
1:400 (Abgent). Anti-rabbit Alexa Fluor 647 was used to
visualize CD11b staining in combination with SMA-FITC.
Anti-CD31/PECAM staining was visualized using anti-rat
biotinylated secondary antibody and Elite ABC Kit (Vector
Laboratories). Immunoﬂuorescence was visualized on a Zeiss
confocal microscopy system. Blood vessel density was
quantiﬁed by examining at least 4 similarly oriented sections
from 4 independent samples in blinded fashion. Isotype
controls were used to validate all antibodies used in this
study. Macrophages were considered to be associated with
blood vessels if they were located within 20 lm.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining was performed on parafﬁn-embed-
ded sections immediately after repetitive ischemia as spec-
iﬁed by the manufacturer (In Situ Cell Death Detection Kit;
R&D Systems). Picrosirius red staining was performed
10 days after repetitive ischemia. For perfusion casting,
Microﬁl perfusion reagent (yellow, Microﬁl, Flow Tech, Inc)
was perfused retrograde into the ascending aorta per the
manufacturer’s speciﬁcations. To preferentially visualize
the arterial tree, microﬁl injection was discontinued once
the coronary sinus began ﬁlling. Left coronary artery (LCA)
and right coronary artery (RCA) sizes were quantiﬁed by
measuring the area the vessel covered within a region of
interest (ROI). Hearts were photographed at low magniﬁcation
(920), and third order branches were used to deﬁne the area
covered by the LCA or RCA. Data were displayed as the
percentage of the area the ROI covered. For the LCA, the ROI
was the anterior wall with the LCA oriented in the center of
the region. For the RCA, the ROI was the inferior wall with the
RCA oriented in the center of the region.
Collaterals in Coronary Allograft Vasculopathy
To determine whether macrophages accumulate in human
collateral coronary arteries, we examined endomyocardial
biopsy specimens from patients with coronary allograft
vasculopathy (CAV). Myocardial biopsy specimens that were
previously collected for routine clinical care were obtained
from the department of pathology. Before study initiation,
institutional review board approval was obtained and the
study was conducted in accordance to the approved protocol.
Collected tissues were previously ﬁxed in 10% formalin and
stored in parafﬁn blocks. For patients with CAV, specimens
were collected within 1 to 2 months of diagnosis and
demonstrated minimal acute cellular rejection (grade O or
1A rejection). Appropriately matched control specimens were
randomly selected based on the duration from transplanta-
tion, experienced fewer than 2 episodes of prior rejection
and were free from major medical comorbidities such as
end-stage renal disease, malignancy, or chronic infection.
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Myocardial biopsy specimens were cut into 4-lm sections
using standard techniques and mounted on glass slides. Each
parafﬁn block typically contained 3 or 4 myocardial spec-
imens. Immunohistochemistry was performed using CD68
(KP1). The primary antibody was detected using HRP conju-
gated secondary antibodies and DAB substrate. CD68 immu-
nostained sections were counterstained with hematoxylin.
These assays were performed by the Anatomic and Molecular
Pathology core as a component of the Institute of Clinical and
Translational Science at Washington University School of
Medicine. CD68-positive staining was quantiﬁed using the
following protocol. For each myocardial specimen, 2 inde-
pendent ﬁelds from each of 3 stained sections were
photographed at 920 magniﬁcation. Image J software was
used to quantify the percent area stained. The resulting
measurements were then averaged to produce a single value
to be used in the ﬁnal analysis. The number of perivascular
CD68+ cells was quantiﬁed by manually counting the number
of CD68+ cells located within 20 lm of intramyocardial blood
vessels per ﬁeld. All specimens were stained, photographed,
and quantiﬁed in blinded fashion.
RNA Isolation, cDNA Synthesis, and, Quantitative
RT-PCR
RNA was isolated from 4 independent biological samples
using the RNeasy kit (Qiagen). cDNA was synthesized using
the high-capacity cDNA reverse transcription kit (Ambion).
Quantitative RT-PCR was performed on an ABI 7200 machine
using either TaqMan-based or SYBR green–based assays.
Taqman probes for Vegf-A, Vegf-B, Vegf-C, Vegf-D, Angpt1,
Angpt2, Ptch1, Fgf2, Pdgf-b, Tgfb1, Tgfb2, Tgfb3, and Hprt
were purchased from Applied Biosystems. SYBR green
primers were obtained from IDT. All samples were normalized
to Hprt or Gapdh and then scaled relative to controls, where
control samples were set at a value of 1. Thus, results for all
experimental samples were graphed as relative expression
compared with control.
Microarray Analysis
RNA was harvested as described and analyzed in the Genome
Technology Access Center microarray core facility at Wash-
ington University. RNA from 4 independent biological samples
was hybridized to the Illumina mouse Ref8 BeadDhip platform.
Quality control standards for hybridization, labeling, staining,
background signal, and basal level of housekeeping gene
expression for each chip were performed and veriﬁed.
Following hybridization, the microarray was scanned and
analyzed using the GenomeStudio software (Illumina, Inc).
Background subtraction, log transformation, and quantile
normalization were performed using Partek GS (Partek).
Hierarchical clustering and PCA analysis were used to access
data quality. Differentially expressed genes were identiﬁed
using a threshold change of 1.4-fold and unadjusted P-value
<0.05 by ANOVA. We used a threshold change of 1.4-fold to
enrich for alterations in gene expression that were most likely
to have a functional impact on phenotype at the expense of
decreased sensitivity. Gene Ontology (GO) pathway analysis
using the Database for Annotation Visualization and Inte-
grated Discovery (DAVID) to identify signaling pathways that
were signiﬁcantly altered.
Statistical Analysis
Data are expressed as meanSD. Student’s t test or ANOVA
was used for comparisons between groups. P-values of <0.05
were considered signiﬁcant. Bonferroni correction was per-
formed when multiple hypotheses were tested. In these cases,
the type I error (a=0.05) was split equally among each test such
that P <0.025 and <0.017 indicated statistical signiﬁcance
after correction for testing 2 or 3 hypotheses, respectively.
Results
Mouse Model of Repetitive Ischemia
To determine whether brief episodes of repetitive ischemia
constitute a sufﬁcient stimulus to trigger coronary growth, we
subjected animals to 15-minute episodes of repetitive LAD
ischemia using the closed-chest I/R system (Figure 1A and
1B). The extent of cardiac dysfunction after a single 15-minute
episode of I/R injury was examined by serial echocardio-
graphic analysis of LV function. At baseline, instrumented
animals demonstrated a small focal wall motion abnormality
located in the anterior wall adjacent to the occluder but had
preserved global systolic function. Immediately after the
induction of ischemia, LV systolic function decreased and a
large wall motion abnormality was present affecting the
anterior, apical, and distal portions of the inferior wall. At
10 minutes after reperfusion, systolic function improved;
however, a large residual wall motion abnormality persisted.
LV systolic function and wall motion returned to baseline
24 hours after reperfusion (Figure 1C through 1H). Revers-
ibility of myocardial dysfunction was similarly observed after 3
serial episodes of ischemia on alternate days (data not shown).
Histological examination of cardiac tissue after 3 episodes
of repetitive ischemia did not reveal evidence of gross
cardiomyocyte disarray, myocardial necrosis, inﬂammatory
cell inﬁltration, or scar formation as typically seen after MI
(Figure 1I). TUNEL staining demonstrated rare foci of cardio-
myocyte cell death and Picrosirius red staining showed
minimal myocardial ﬁbrosis within the ischemic area after 3
episodes of repetitive ischemia (Figure 1J and 1K). While
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Figure 1. Mouse model of ischemia-induced coronary angiogenesis. A, Diagram depicting the closed-chest ischemia reperfusion model. An
occluder is loosely placed around the LAD proximal to the major lateral branch. Ischemia is induced by placing tension on a suture threaded through
the occluder. The yellow area indicates the ischemic territory and representative ECGs are shownbefore and during ischemia. B, Schematic describing
the repetitive ischemia protocol.Micewere instrumented 2 weeks before the induction of ischemia. Ischemiawas induced for 15 minutes every other
day and animals were analyzed during the next 7 days. C through F, End-systolic images after 15 minutes of ischemia. The dashed yellow line
indicates the location of a wall motion abnormality, and the dashed blue line denotes the endocardial border. Prior to the inducing of ischemia (C),
there is a small wall motion abnormality that corresponds to the site of occluder placement. Induction of a single episode of ischemia (D) results in a
largewall motion abnormality extending from the anterior wall to themid inferior wall. Immediately after reperfusion (E), there is a residual wall motion
abnormality that resolveswithin 24 hours (F). G andH, Quantiﬁcation of ejection fraction and akinetic region at baseline, during ischemia, 10 minutes
after reperfusion, and 24 hours after reperfusion. *P<0.05 compared with baseline and 24 hours after reperfusion, **P<0.017 compared with all
other time points. I, H&E–stained sections showing normal myocardial architecture after 3 episodes of repetitive ischemia. J, TUNEL staining
demonstratingminimal cell death (white arrowheads) after 3 episodes of repetitive ischemia. K, Picrosirius red staining showingmyocardial ﬁbrosis in
sham and mice that underwent 3 episodes of repetitive ischemia. L, Quantiﬁcation of TUNEL and Picrosirius red staining. **P<0.025 compared with
all other groups. Ao indicates aorta; ECG, echocardiography; H&E, hematoxylin and eosin; IR, ischemia and reperfusion; LAD, left anterior descending
coronary artery; LCA, left coronary artery; LCX, left circumﬂex artery; LPL, lateral posterior lateral branch; LV, left ventricle; RCA, right coronary artery;
RSC, right septal conal branch; RV, right ventricle; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
DOI: 10.1161/JAHA.113.000343 Journal of the American Heart Association 5















quantiﬁcation of TUNEL-positive cells and ﬁbrotic area
demonstrated signiﬁcant increases in myocardial cell death
and ﬁbrosis after repetitive ischemia, these events were
minimal compared with mice that underwent 90 minutes of
I/R injury (Figures 1L and S1). Due to the low frequency of
cell death after repetitive I/R injury, we did not further
delineate which cell types were most affected. These data
indicate that brief episodes of I/R injury lead to reversible
cardiac dysfunction with minimal myocardial ﬁbrosis and cell
death, as previously reported.30–33
Repetitive LAD Ischemia Is Sufﬁcient to Promote
Coronary Growth
To determine whether repetitive ischemia is sufﬁcient to
trigger coronary growth, we examined the coronary macro-
vasculature and microvasculature after 3 rounds of repet-
itive ischemia. One week after repetitive LAD ischemia, the
coronary arterial tree was visualized using microﬁl perfusion
casting (Figure 2A through 2H). These experiments revealed
that both sham and repetitive ischemia animals had similar
LCA size as expressed by area of the ROI (anterior wall)
covered (65.7% versus 63.9%, P=0.61). In contrast, mice
subjected to repetitive ischemia demonstrated signiﬁcant
growth of the RCA (Figure 2I). In sham animals, the RCA
was small compared with the LCA and covered only the
basal inferior wall. In mice that underwent repetitive LAD
ischemia, the RCA covered the entire inferior wall and
contained branches extending toward the lateral and septal
walls. This represented nearly a 3-fold increase in RCA size
(32.9% versus 77.3%, P<0.05). While the lateral wall was
supplied by diagonal branches of the LAD in shams, mice
Figure 2. Induction of coronary growth after repetitive ischemia. A–H, Microﬁl perfusion casts demonstrating enlargement of the RCA after
repetitive LCA ischemia. Sham animals (A–D) display a large LCA (A) and rudimentary RCA (B). The lateral wall is perfused through diagonal
branches of the LAD (C and D). Following repetitive ischemia, the LAD (E) appears unchanged compared with sham-operated animals, while the
RCA undergoes signiﬁcant enlargement (F). In these animals, the lateral wall is perfused by both the RCA (white arrow) and diagonal branches
arising from the LAD (G and H). The white rectangle denotes the area enlarged in (D and H). I, Quantiﬁcation of the area covered by the LAD and
RCA. *P<0.05 compared with sham. LAD indicates left anterior descending coroney artery; LCA, left coronary artery; RCA, right coronary artery.
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that underwent repetitive ischemia demonstrated contribu-
tions from both diagonal branches and the RCA (Figure 2G
and 2H, arrows).
To visualize intramyocardial arterioles and the microvas-
culature, we performed smooth muscle actin and CD31/
PECAM immunostaining, respectively. For PECAM staining, we
quantiﬁed the area stained using an automated method to
estimate blood vessel density (Figure S2). Compared with
sham animals, mice that were subjected to repetitive
ischemia had increased capillary density in both the ischemic
area and border zone (Figure 3A and 3B). No change in
microvascular density was seen in the remote area (data not
shown). Increased microvascular density was observed in
both regions for at least 1 week after 3 episodes of repetitive
ischemia and peaked at day 3 (Figure 3D and 3E). Consistent
with this angiogenic response, similar increases in intramyo-
cardial coronary arteriole number were seen in mice that
underwent repetitive ischemia (Figure 3C and 3F).
Figure 3. Microvascular expansion after repetitive ischemia. A and B, CD31/PECAM immunohistochemistry revealing expansion of the
microvasculature in both the ischemic area (A) and border zone (B) after repetitive ischemia. C, Smooth muscle (SM) actin immunohistochemistry
showing increased numbers of intramyocardial coronary arterioles in mice that underwent repetitive ischemia. D and E, Quantiﬁcation of
microvascular area stained in the ischemic area (D) and border zone (E) showing signiﬁcant increases in capillary density peaking day 3 after repetitive
ischemia. F, Quantiﬁcation of the number of SM actin–containing blood vessels per 910 ﬁeld demonstrating increased intramyocardial arteriole
number in mice that underwent repetitive ischemia at all time points examined. *P<0.05 compared with sham and day 3 after repetitive ischemia,
**P<0.017 compared with all other time points. A and B, 920 and C, 910. PECAM indicates platelet endothelial cell adhesion molecule.
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Ischemia-Induced Coronary Growth Protects
From MI by Decreasing the Area at Risk
To determine if repetitive ischemia-driven coronary growth is
physiologically relevant, we examined whether repetitive
ischemia protected from prolonged I/R injury. For these
experiments, mice were subjected to 3 rounds of repetitive
ischemia followed by prolonged (120 minutes) I/R injury
10 days later (Figure 4A). One hundred twenty minutes of
ischemia was selected because it produces a large anterior
wall infarct similar to chronic LAD ligation.34 We chose to
subject animals to MI 10 days after repetitive ischemia to
minimize the effects of preconditioning.35,36
Echocardiographic imaging was performed at baseline,
immediately after MI, and 28 days after MI to assess the
initial ischemic area, changes in LV systolic function, and LV
remodeling. Immediately after MI, sham and repetitive
ischemia animals demonstrated comparable wall motion
abnormalities. The percentage of the ventricle that was
akinetic (45.9% versus 48.1%, P=0.70) and LV EF (32.7%
versus 29.8%, P=0.21) were comparable, indicating similar
extents of injury between experimental groups. Sham
animals displayed reduced EF immediately after MI, failed
to recover LV systolic function over the next 28 days, and
had increased LV chamber size consistent with the develop-
ment of adverse remodeling. In contrast, mice subjected to
repetitive ischemia demonstrated signiﬁcant relative improve-
ments in EF and did not undergo LV dilation 28 days after MI
(Figure 4B through 4F).
Histological examination of hearts after prolonged I/R
injury revealed a signiﬁcant regional decrease in the area of
trichrome staining in the LV inferior and lateral walls of mice
subjected to repetitive ischemia compared with sham controls
(11.0% versus 21.3%, P<0.01), consistent with less extensive
infarction (Figure 5A through 5C). While we cannot exclude
other mechanisms such as alterations in scar contraction,
these ﬁndings are consistent with the pattern of RCA growth
visualized by arterial casting and suggest that coronary
growth and improved blood ﬂow to the inferior and lateral
walls may account for the smaller infarct sizes and improved
LV function in the mice that underwent repetitive coronary
ischemia.
To further explore this possibility, we performed Evans blue
perfusion staining after either 3 or 6 rounds of repetitive
ischemia (Figure 5D through 5F). Compared with sham
animals that displayed a large area at risk encompassing
the anterior, lateral, and inferior walls, mice that underwent
repetitive ischemia had a smaller area at risk (38.4% versus
28.5%, P<0.01). Mice subjected to 3 rounds of ischemia
demonstrated a localized area at risk in the anterior and
lateral walls, sparing the inferior wall. Further reductions in
area at risk were observed in mice that underwent 6 rounds of
repetitive ischemia (19.9%, P<0.05 compared with the other
groups). Together, these data indicate that repetitive ischemia
promotes coronary growth and protects from MI by decreas-
ing the area at risk, consistent with regional improvements in
myocardial perfusion. Moreover, these effects are dose
dependent.
Expression Proﬁling During Ischemia-Induced
Coronary Growth
We performed microarray-based gene expression proﬁling to
search for genes and pathways involved in ischemia-induced
coronary growth. RNA was isolated from the ventricular
myocardium of animals that were subjected to 3 rounds of
repetitive ischemia. To gain insights into temporal changes in
gene expression, hearts were harvested on days 1, 3, and 5
after the third ischemic episode. Using a threshold of 1.4-fold,
we observed that compared with sham animals, the largest
changes in gene expression occurred within the ﬁrst few days
after repetitive ischemia. Four hundred ﬁve genes (277
upregulated, 128 downregulated), 129 genes (105 upregulat-
ed, 24 downregulated), and 40 genes were altered on days 1,
3, and 5 after repetitive ischemia, respectively (Figure 6A,
Tables S1 through S3). Consistent with these results,
hierarchical clustering revealed that the largest alterations
in global gene expression occurred at day 1 after repetitive
ischemia, whereas the changes in gene expression were less
marked on days 3 and 5 (Figure 6B).
GO pathway analysis uncovered enrichment of genes
belonging to pathways associated with innate immunity,
extracellular matrix (ECM) structure, and blood vessel devel-
opment on day 1 after repetitive ischemia (Figure 6, Table). In
contrast, on day 3 after repetitive ischemia, there was a shift
in gene expression from genes involved in innate immunity
and inﬂammation pathways toward pathways associated with
cell adhesion, ECM organization, and vascular development.
Given the smaller number of genes with altered expression on
days 5 after repetitive ischemia, no pathways were signiﬁ-
cantly altered in this analysis.
Classic Proangiogenic Factor Expression During
Ischemia-Induced Coronary Growth
Despite regulation of pathways associated with blood vessel
development on days 1 and 3 after repetitive ischemia, we
were surprised to ﬁnd that microarray proﬁling failed to
demonstrate signiﬁcant upregulation of many classically
described proangiogenic factors. To conﬁrm these ﬁndings,
we performed quantitative RT-PCR assays. Consistently, these
experiments failed to show increased expression of several
well-accepted proangiogenic molecules (Figure 7A). We could
not detect any increase in Vegf-A, Vegf-B, Vegf-C, Vegf-D, Pgf,
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Figure 4. Ischemia-induced coronary angiogenesis protects from myocardial infarction. A, Schematic depicting the experimental protocol used
to test whether repetitive ischemia-induced coronary growth protects from myocardial infarction. Echocardiograms were performed at baseline,
during ischemia before myocardial infarction (ischemia) to control for variations in ischemic area, and 28 days after myocardial infarction (day
28). B and C, End-systolic images during LAD ischemia at baseline and 28 days after myocardial infarction demonstrating that compared with
sham-operated animals (B), animals that underwent repetitive ischemia (C) have a smaller wall motion abnormality after myocardial infarction. D,
Pairwise quantiﬁcation of akinetic area revealing that sham animals have no change in akinetic area between ischemia and 28 days after
myocardial infarction. In contrast, animals that underwent repetitive ischemia have a smaller akinetic area after myocardial infarction. E, Pairwise
quantiﬁcation of EF revealing that sham animals have no improvement in EF between ischemia and 28 days after myocardial infarction. In
contrast, animals that underwent repetitive ischemia have improved EF after myocardial infarction. F, Pairwise quantiﬁcation of LV remodeling as
assessed by LV diastolic dimension indexed to body weight revealing that sham animals undergo increased LV size between ischemia and
28 days after myocardial infarction. In contrast, animals that underwent repetitive ischemia have a slight reduction in LV dimension. Also, Δ
akinetic area, EF and LV volume index indicate change between ischemia and 28 days after MI. *P<0.05 compared with sham. EF indicates
ejection fraction; LAD, left anterior descending coronary artery; LV, left ventricle; MI, myocardial infarction.
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Pdgf-b, Tgfb1-3, Ptch1, Thymosinb4, Mmp2, Mmp9, Nos2, or
Nos3 mRNA expression. In contrast, we did observe modest
increased expression of Fgf2 and Angpt2. Each of these
factors has been implicated in either hindlimb ischemia or MI
border zone angiogenesis models.11,12,19–22,26,27,39,40
Given the fundamental importance of VEGF signaling in
vascular growth, we further examined whether VEGF-A might
be modulated on the protein level. We performed VEGF-A
immunostaining on sections obtained from sham controls,
mice subjected to repetitive ischemia, or mice that underwent
experimental MI. Sections were co-stained for cardiac actin to
identify cardiomyocytes and the border zone. Only low levels
of VEGF-A protein could be detected in the myocardium from
sham and repetitive ischemia animals. In contrast, robust
VEGF-A protein expression was observed in the border zone
after MI (Figure 7B). Consistent with these results, Western
blotting demonstrated comparable VEGF-A protein levels in
sham-operated mice and mice that underwent repetitive
ischemia (Figure 7C). These data strongly suggest that classic
proangiogenic growth factors previously implicated in hind-
limb ischemia models and experimental MI models are not
involved in ischemia-induced coronary growth.
Involvement of Macrophages in Ischemia-Induced
Coronary Growth
As noted, GO pathway analysis revealed selective regulation
of genes associated with innate immune responses on day 1
after repetitive ischemia (Table). To further explore the
possibility that the innate immune system might be involved
in ischemia-induced coronary growth, we examined sections
of cardiac tissue in the area at risk after repetitive ischemia.
Histological analysis revealed a cellular inﬁltrate surrounding
intramyocardial blood vessels, present at days 1 and 3 after
repetitive ischemia. The cellular inﬁltrate largely resolved by
day 5 (Figure 8A). Immunohistochemical staining demon-
strated that these cells expressed MAC3 and CD11b consis-
tent with macrophages (Figures 8B and S3). Further
characterization showed that these cells were negative for
Gr1, CD11c, CD3, CD19, and NK1.1 (Figure S1, data not
shown). Co-labeling with CD11b and smooth muscle actin
antibodies conﬁrmed the presence of macrophages associ-
ated with the intramyocardial coronary vasculature (Figure 8C
and 8D). Quantitative analysis demonstrated signiﬁcantly
increased number of MAC3- and CD11b-positive cells
Figure 5. Reduced infarct size and decreased area at risk after ischemia induced angiogenesis. A and C, Compared with sham-treated animals,
repetitive ischemia resulted in decreased infarct size after myocardial infarction. Whole mount (A) and trichrome-stained sections (B) reveal
decreased scar size in animals that underwent repetitive ischemia compared with shams. The black arrow indicates that position of the left
anterior descending coronary artery (LAD) occluder and the blue dashed lines mark the border between scar and viable muscle. Quantiﬁcation of
infarct size (C) demonstrates smaller infarcts after repetitive ischemia. *P<0.05 compared with sham. D and F, Evans blue perfusion staining (D)
and respective threshold images (E) during LAD ischemia demonstrating a dose-dependent decrease in area at risk in animals that underwent
repetitive ischemia. The dashed yellow line (D) and solid blue lines (E) outline the area at risk. Quantiﬁcation of area at risk (F) showing a dose
dependent decrease after repetitive ischemia. **P<0.025 compared with all other time points.
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surrounding the vasculature in mice that underwent repetitive
ischemia (Figure 8E and 8F). These data are consistent with
prior studies demonstrating a role for macrophages in
collateralization during hindlimb ischemia.41
To further support a putative role for macrophages in
ischemia-driven coronary growth, we performed quantitative
RT-PCR assays to conﬁrm changes in the expression of genes
associated with macrophage activity. We included genes that
were identiﬁed through our microarray experiments as well
those that have been previously demonstrated to be impor-
tant for macrophage recruitment, macrophage-derived cyto-
kine signaling, and ECM remodeling. This analysis
demonstrated robust increases in the expression of numerous
chemokines and cytokines including Mcp1, Mcp3, Mip1a,
Mip1b, Mip1c, Rantes, IL-1b, IL-6, and Socs3. In addition,
we were able to detect increased expression of multiple
macrophage-associated genes previously implicated in ECM
remodeling including Timp1, Ctgf, Integrin a5, and Galectin 3
(Figure S4). These data implicate potential roles for innate
immunity, macrophage recruitment, and ECM remodeling in
ischemia-induced coronary growth.
To determine whether these ﬁndings in mice also pertain
to growth of collateral arteries in humans, we questioned
whether macrophages surround the intramyocardial vascula-
ture in humans with coronary collaterals. For these studies,
we obtained endomyocardial biopsy specimens from patients
with CAV. CAV is a vascular process with similarities to native
coronary artery disease that diffusely affects the coronary
Figure 6. Microarray gene expression proﬁling during ischemia-induced coronary angiogenesis. A, Venn diagram describing the distribution of
upregulated and downregulated genes at day 1, 3, and 5 after repetitive ischemia compared with sham controls. B, Hierarchical cluster analysis
revealing that the largest changes in gene expression occurs at days 1 and 3 after repetitive ischemia. C, Bar graphs depicting the number of
genes regulated for each pathway identiﬁed through GO pathway analysis. ECM indicates extracellular matrix; GO, Gene Ontology.
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tree and is among the leading causes of mortality and
allograft failure after cardiac transplantation.42,43 Given the
diffuse nature of this vascular process and ease of access to
biopsy tissue, CAV represents a potential model disease to
study coronary collateral growth. In support of this notion, we
have previously demonstrated that the development of
angiographically visible collaterals in patients with CAV is
associated with improved survival and allograft function.44
We obtained endomyocardial biopsy specimens suitable for
immunohistochemical analysis from 23 control patients, 21
CAV patients without collaterals, and 30 CAV patients with
angiographically visible collaterals. CD68 immunostaining
demonstrated that compared with controls, CAV patients had
higher numbers of macrophages surrounding the intramyocar-
dial vasculature. CAV patients with collaterals had more
perivascular macrophages than both CAV patients without
collaterals and control patients (Figure 8G and 8H). Interest-
ingly, while CAV patients lacking collaterals had the largest
total number of macrophages (Figure S5), the majority of these
cells were interstitial, rather than perivascular. As co-labeling
experiments were not technically feasible in these specimens
and perivascular location was inferred by morphologic criteria,
we were not able to precisely determine which type of
vasculature was associated with CD68-positive macrophages.
Discussion
Using repetitive I/R injury to mimic the phenomenon of
stuttering angina, we demonstrate that repetitive brief
episodes of LAD ischemia are sufﬁcient to trigger expansion
of coronary growth on the macrovascular and microvascular
levels in a closed-chest murine model of ischemic injury
(Figures 2 and 3). We further show that ischemia-induced
coronary growth is functionally signiﬁcant and leads to a
decrease in the area at risk, as measured by using Evans blue
staining, as well as decrease in infarct size, improved cardiac
remodeling and improved LV ejection fraction after prolonged
ischemic injury (Figure 4). Transcriptional proﬁling of hearts
subjected to repetitive bouts of brief ischemia disclosed
minimal alterations in the temporal expression of classic
proangiogenic growth factors but did reveal a potentially
important role for genes involved in innate immunity, cardiac
macrophages, and ECM remodeling. Moreover, histological
analysis of mouse hearts subjected to repetitive bouts of
ischemia disclosed the presence of macrophages surrounding
intramyocardial blood vessels, consistent with prior studies
that have suggested a role for macrophages in the develop-
ment of collateral vessels during hindlimb ischemia.41 Viewed
together, these studies suggest that brief episodes of
repetitive myocardial ischemia provoke increased coronary
growth that is sufﬁcient to protect the heart against
prolonged ischemic injury and implicate a potential novel
role for the cardiac macrophage as a potential mediator of
ischemia-driven coronary growth.
Expression of Classic Proangiogenic Factors
During Ischemia-Induced Coronary Growth
To our surprise, both candidate and unbiased gene expression
proﬁling revealed minimal alterations in the expression of
Table. GO Pathway Analysis of Gene Expression Following Repetitive Ischemia
GO Pathway n (Genes) P Value Bonferroni Genes
Day l Blood vessel development
GO:0001568
24 1.16E-09 2.08E-06 NRP1, EGFL7, SOCS3, TNFRSF12A, TGFBR1, COL3A1, SPHK1, MMP14,
CXCL12, MMP2, JUNB, COL5A1, ANXA2, NUS1, CTGF, AGTR1A, AGT,
HMOX1, HBEGF, COL1A1, LOX, TNFAIP2, ANGPT2, CYR61
ECM organization
GO:0043062
18 1.06E-08 1.91E-05 LGALS3, OLFML2B, TGFBR1, TNC, COL3A1, CCDC80, KY, VTN, COL5A1,
ANXA2, AGT, PDGFRA, LOX, LAMC1, APBB2, ADAMTS2, CYR61, F2R
Immune response
GO:0006955
29 4.48E-07 8.06E-04 ENPP1, UNG, TLR2, CCL9, CXCL9, TLR4, VTN, CXCL12, CCL4, TLR7, CCL7,
CCL6, TAP2, BCL6, CLEC4D, PTX3, ICAM1, TLR13, CLEC4N, FCGR3, PPBP,
vFCGR2B, CCR5, SERPINA3G, KCNJ8, P2RY14, GADD45G, CD300LG, CD14
Inflammatory response
GO:0006954
19 9.11E-07 1.64E-03 NFKBIZ, TLR13, SPHK1, CXCL9, TLR2, TLR4, TLR7, CCL4, CCL7, STAT3,
FCGR3, SERPINA3N, CCR5, CD44, ITGB6, NPPB, THBS1, CD14, F2R
Day 3 Cell adhesion
GO:0007155
16 3.73E-06 3.34E-03 AEBP1, IGFBP7, COL15A1, ITGA11, COL16A1, SIRPA, COL5A1, SCARF2,
ITGBL1, LYVE1, CPXM1, COL6A1, LAMC1, GPNMB, MFAP4, THBS2
Vasculature development
GO:0001944




7 5.46E-05 4.78E-02 LGALS3, TGFBR1, COL3A1, CCDC80, LAMC1, ADAMTS2, COL5A1
Day 5 None
Blue genes were upregulated and red genes were downregulated. ECM indicates extracellular matrix; GO, gene ontology.
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Figure 7. Classic proangiogenic growth factor expression after repetitive coronary ischemia. A, Quantitative RT-PCR assays showing expression
of classic proangiogenic growth factors in hearts 1 day after repetitive ischemia relative to sham controls. Only Angpt2 and Fgf2 were
upregulated after repetitive ischemia. *P<0.05 compared with sham. B, Immunostaining revealing unchanged VEGF-A expression (red) in mice
that underwent repetitive ischemia compared with sham controls. In contrast, VEGF-A expression is increased in the border zone after myocardial
infarction. DAPI (blue) and cardiac actin (cActin, green) demarcate the border zone. C, Western blot demonstrating no change in VEGF-A protein
levels between sham control and hearts that underwent repetitive ischemia. DAPI indicates 40,6-diamidino-2-phenylindole; FGF, ﬁbroblast growth
factor; VEGF, vascular endothelial growth factor.
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Figure 8. Macrophages surround the coronary vasculature during ischemia induced coronary angiogenesis. A, H&E staining (920) showing a
cellular inﬁltrate in the adventitia of intramyocardial coronary blood vessels (arrows) after repetitive ischemia. The inﬁltrate resolves by day 5
after repetitive ischemia. B, Immunostaining for MAC3 (940) demonstrating that the cellular inﬁltrate is primarily composed of macrophages.
C and D, Immunostaining for CD11b (magenta) and smooth muscle actin (SMA, green) demonstrating that compared with sham controls (C),
there is an enrichment of macrophages surrounding intramyocardial blood vessels after repetitive ischemia (D). (Original magniﬁcation 963,
scale bar indicates 20 lm.) E and F, Quantiﬁcation of MAC3- and CD11b-positive cells in sham controls and mice that underwent repetitive
ischemia. G, CD68 immunostaining (940) of endomyocardial biopsy specimens from controls and patients with CAV according to the presence
of collaterals showing increased numbers of perivascular macrophages in patients with CAV who have collateral vasculature. Scale bar
indicates 40 lm. H, Quantiﬁcation of perivascular macrophages displayed as the number of macrophages per blood vessel (BV). *P<0.05
compared with sham. **P<0.017 (E) and P<0.025 (H) compared with all other groups. CAV indicates coronary allograft vasculopathy; H&E,
hematoxylin and eosin; MAC3, CD107b.
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multiple classic proangiogenic growth factors after repetitive
bouts of ischemic injury that were sufﬁcient to provoke
coronary growth. Many of these molecules are required for
collateral growth during hindlimb ischemia and border zone–
associated coronary angiogenesis after experimental MI.
Among these, VEGF-A is the best studied and has been
implicated in most forms of blood vessel growth.34 Surpris-
ingly, we were unable to detect increased VEGF-A mRNA or
protein on either the global or local level. Among classic
proangiogenic growth factors, only Fgf2 and Angpt2 were
found to be upregulated during ischemia-induced coronary
growth.
These data suggest that there are fundamental differences
between the molecular mechanisms that govern ische-
mia-induced coronary growth, coronary angiogenesis after
experimental MI, and hindlimb ischemia. For example, robust
increases in VEGF-A expression are readily detectable after
hindlimb ischemia or experimental MI.12,13,15,17 Surprisingly,
we did not observe similar increases in VEGF-A or several
other classic proangiogenic growth factors during repetitive
ischemia-driven coronary growth. Although speculative, these
ﬁndings may offer one potential explanation for why thera-
peutic angiogenesis trials using classic proangiogenic factors
in patients with ischemic heart disease have failed to
signiﬁcantly improve clinical outcomes.
Role of the Innate Immune System and Cardiac
Macrophage in Ischemia-Induced Coronary
Growth
Expression proﬁling and GO pathway analysis revealed a
potential role for innate immunity as a potentially important
driver of ischemia-induced coronary growth. Multiple mono-
cyte- and macrophage-associated chemokines and cytokines
were upregulated after repetitive ischemia and may mediate
recruitment of macrophages to growing vasculature. Although
this study was not intended to delineate the proximate
mechanisms of innate immune activation after repetitive I/R
injury, it is noteworthy that increased oxidative stress after I/
R injury is sufﬁcient to activate proinﬂammatory cyto-
kines.31,33 Furthermore, we demonstrated that macrophages
surround small intramyocardial arterioles during periods of
coronary growth. Consistent with a role for macrophages in
human coronary collateral development, immunostaining of
biopsy specimens from CAV patients revealed that those with
collaterals had signiﬁcantly increased numbers of CD68-po-
sitive macrophages surrounding intramyocardial blood
vessels.
These ﬁndings are consistent with the known role for
innate immunity and macrophages in hindlimb collateral
development. Mice deﬁcient in CCR2 display diminished
numbers of macrophages surrounding collateral blood vessels
and impaired ability to generate collaterals after hindlimb
ischemia.45 Conversely, infusion of MCP-1 (ligand for CCR2)
improves collateral growth.46 Csfop/op mice, which are
deﬁcient in monocytes and macrophages, have impaired
collateral growth, and infusion of granulocyte colony-stimu-
lating factor is sufﬁcient to promote collateral growth after
hindlimb ischemia.47,48 Together, these data suggest that
macrophages are important mediators of collateral growth in
the periphery. The molecular mechanism by which macro-
phages mediate collateral growth in this setting are largely
unknown but are thought to involve direct contact with
endothelial cells, macrophage-derived proangiogenic growth
factors, and cytokines.41
Consistent with a conserved role for macrophages in
coronary collateral growth, infusion of granulocyte col-
ony-stimulating factor into patients with ischemic heart
disease improved collateral ﬂow as measured by collateral
ﬂow index.49 Whether cardiac macrophages are necessary for
adult coronary growth and whether cardiac macrophages
mediate vascular growth through mechanisms similar to those
used in hindlimb ischemia models are unknown and will
undoubtedly be a topic of future investigation. The develop-
ment of genetically tractable models of coronary growth, such
as presented here, will likely aid in the ability of investigators
to answer these questions.
Limitations
While the experiments presented here implicate activation of
the innate immune system and involvement of cardiac
macrophages in ischemia-driven coronary growth rather than
classic proangiogenic growth factors, we have yet to
rigorously prove this is the case. Further studies using
genetic tools will be essential to appropriately deﬁne the
requirement for macrophages in this process. In addition,
identifying potential triggers of innate immune system
activation such as generation reactive oxygen species and
ultimately deﬁning the molecular mechanisms by which they
may govern coronary growth represent important issues that
are yet to be resolved.
Although we cannot formally exclude a potential role for
preconditioning as a mechanism for the smaller infarct size
and improved cardiac remodeling and improved LV function in
the mice subjected to repetitive ischemia, we believe that this
is unlikely for 3 reasons. First, the early and late windows of
preconditioning occur within 1 to 2 hours and 3 to 5 days,
respectively, after ischemic injury.35,36 Thus, based on the
timing of the prolonged ischemic injury (10 days after
repetitive ischemia), preconditioning is unlikely to explain
our ﬁndings. Further, the observation that the extent of LV
dysfunction and LV dilation were not different in the sham and
repetitive ischemia groups of mice immediately after pro-
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longed I/R injury also suggests that preconditioning was not
the major mechanism for the observed ﬁndings. Third, we did
not observe a signiﬁcant upregulation of genes implicated in
late preconditioning such as iNos and Cox. Thus, our data
suggest that increased coronary growth is the most likely
mechanism for the decrease in infarct size and improved LV
structural and functional recovery after prolonged ischemic
injury.
Conclusions
Using a clinically relevant closed chest mouse model of
ischemic injury, we show for the ﬁrst time that brief bouts of
repetitive myocardial ischemia provoke increased coronary
growth that is sufﬁcient to protect the heart against
prolonged ischemic injury. These results are important for 2
reasons. First, although these studies did not identify an
important role for the classic proangiogenic growth factors,
they do suggest a potentially important role for innate
immunity and cardiac macrophages in terms of mediating
coronary growth. Second, these studies clearly demonstrate
that coronary growth can be studied longitudinally using a
tractable closed chest mouse model that can be genetically
manipulated. Indeed, studies that have examined the molec-
ular mechanisms for coronary angiogenesis and collateraliza-
tion thus far rely on large animal models that are not
amenable to genetic dissection, and/or rely on surrogate
processes such as hindlimb ischemia in the mouse. While
some mechanisms for angiogenesis are likely to be con-
served in different experimental model systems, it is not clear
to what extent signaling pathways that control collateraliza-
tion in the hindlimb are also involved in coronary growth.
Accordingly, subsequent studies using this closed chest
murine model system may advance our understanding of the
basic mechanisms that are responsible for mediating coro-
nary growth and collateralization in the adult mammalian
heart.
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Supplemental figure 1. A, TUNEL staining demonstrating robust cell death in the 
myocardium of mice 24 hours following 90 minutes of IR injury. B, Quantification of 






Supplemental figure 2. A-B, Immunostaining for CD31/PECAM showing increased 
capillary density in mice that underwent repetitive ischemia compared to shams. C, 
Quantification of blood vessel number per 40X field. D, Linear regression analysis 
demonstrating a signficiant correlation between area stained and blood vessel number. 
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 Supplemental Figure 3. Immunostaining for CD11b (A) and Gr1 (B) demonstrating that 























































































































































































































































































Supplemental Figure 4. Quantitative RT-PCR assays demonstrating upregulation of 
chemokines, cytokines, and macrophage-derived factors in involved in macrophage 











 Supplemental Figure 5. Quantification of the total number of macrophages (CD68+ 
cells) in endomyocardial biopsy specimens from controls and patients with CAV 
according to the presence of collateral vasculature. Macrophage density is displayed as 
the percent area stained. ∗ denotes p<0.05 compared to controls. 
  
∗
Supplemental Table 1. Significant alterations in gene expression between sham and 
repetitive IR groups (day 1). 
 

























































































































































































































































































































































































































Supplemental Table 2. Significant alterations in gene expression between sham and 
repetitive IR groups (day 3). 
 




































































































































Supplemental Table 3. Significant alterations in gene expression between sham and 
repetitive IR groups (day 5). 
 
Probe ID p-value Fold change
Acta1 4.58E-04 3.07
Ankrd1 1.46E-03 1.91
Nppa 4.46E-03 1.64
Nppb 1.56E-02 1.62
Ankrd23 3.08E-04 1.62
Mmp2 2.14E-03 1.61
Pja2 1.04E-04 1.59
Ptgds 7.20E-03 1.58
Ahnak2 3.90E-04 1.57
Col4a1 3.03E-03 1.55
Itgbl1 2.63E-02 1.55
Ttn 1.59E-03 1.55
Fbn1 2.49E-02 1.52
Uck2 5.99E-04 1.52
Ccdc80 1.53E-03 1.50
Hsp105 1.11E-02 1.49
Retsat 6.61E-04 1.48
Ccdc68 1.66E-05 1.47
Golga4 1.52E-03 1.45
Svep1 1.05E-03 1.45
Gna12 1.49E-03 1.44
Csde1 2.88E-03 1.43
Nav1 2.34E-03 1.42
Ndufb2 2.65E-02 -1.40
Oasl2 1.38E-02 -1.40
Per2 8.81E-03 -1.41
Mylpf 3.75E-02 -1.41
Gzmm 1.23E-03 -1.43
Fam131a 2.39E-03 -1.43
Tmem82 1.38E-02 -1.44
Ier3 2.18E-03 -1.45
Icam1 2.68E-02 -1.49
Bcas2 9.87E-04 -1.50
Lgals4 9.54E-04 -1.54
Erdr1 1.88E-02 -1.57
Tnnt1 7.95E-04 -1.60
Cxcl1 1.70E-02 -1.71
Gsta3 2.31E-03 -1.73
Ndufa5 1.96E-03 -1.76
S100a8 7.25E-03 -3.25
 
